Welcome to our dedicated page for 908 Devices news (Ticker: MASS), a resource for investors and traders seeking the latest updates and insights on 908 Devices stock.
News and updates for 908 Devices Inc. (NASDAQ: MASS) center on its development and deployment of purpose-built handheld devices for chemical analysis in health, safety and defense technology applications. The company reports that its tools are used at the point of need to interrogate unknown and invisible materials and provide quick, actionable answers in situations involving drugs, toxic chemicals and security threats.
Investors and observers following 908 Devices can expect regular news on quarterly financial results, including revenue from product sales, service and contract revenue, recurring revenue tied to its installed base, and non-GAAP measures such as adjusted gross margin and adjusted EBITDA. These updates are often accompanied by commentary on channel mix, recurring revenue trends and strategic focus on handheld chemical analysis tools.
The company also issues news about product developments and launches. Recent announcements describe handheld analyzers that combine FTIR and Raman spectroscopy through proprietary Smart Spectral Processing algorithms, as well as devices designed for rapid field-based identification of unknown bulk solids, liquids, gases and vapors. Such releases highlight capabilities like trace-level detection of drugs, explosives and hazardous materials, wireless connectivity and integration with the 908 Devices Team Leader app.
Another key theme in 908 Devices’ news flow is adoption by government and defense organizations. Public updates have detailed purchases of handheld mass spectrometry and gas identification devices by entities such as the United States Coast Guard and United States Marine Corps for narcotics interdiction, hazardous threat detection and protection of installations and coastal communities.
Corporate governance and investor relations activities also appear in the news stream, including participation in investor conferences, webcasts of earnings calls and changes to the Board of Directors that align with the company’s focus on public health, safety and defense tech. For a comprehensive view of how 908 Devices is executing its strategy, readers can review this evolving news record over time.
908 Devices (Nasdaq: MASS) reported a 52% sequential revenue growth in Q3 2021, totaling $12.5 million, and a 107% increase year-over-year. The installed base grew to 1,714 devices, marking a significant expansion with 184 devices added in Q3 alone. Gross profit reached $6.8 million, with a 54% gross margin. However, operating expenses rose to $12.1 million, contributing to a net loss of $5.2 million. The company forecasts $41 million to $43 million in annual revenue, reflecting a 52% to 60% growth outlook.
908 Devices Inc. (NASDAQ: MASS) launched a new Oligos assay kit at the ASMS conference, designed for its ZipChip device, enabling rapid and accurate oligonucleotide analysis. The kit offers several advantages over traditional liquid chromatography, including:
- No harsh ion-pairing reagents
- Faster analysis
- High-resolution, accurate mass identification
This advancement supports biopharmaceutical labs and enhances 908 Devices' position in the growing market for therapeutic oligonucleotides.
908 Devices Inc. (NASDAQ: MASS) is set to showcase its advancements in mass spectrometry at the ASMS conference from October 31 to November 4 in Philadelphia. The company will highlight novel high-pressure mass spectrometry and microfluidics technologies aimed at accelerating drug discovery in metabolomics and proteomics. Notably, a new ZipChip assay kit will be introduced for rapid oligonucleotide analysis. Presentations will focus on improving analysis time and efficiency in various applications, demonstrating the company's significant role in evolving laboratory mass spectrometry.
908 Devices (NASDAQ: MASS) will report its Q3 2021 financial results before market open on November 4, 2021. Management will host a webcast conference call starting at 5:30 a.m. PT / 8:30 a.m. ET. The event is accessible via the company's website and will be archived for replay within 24 hours. 908 Devices specializes in handheld and desktop mass spec devices aimed at life sciences, bioprocessing, and forensics, enhancing laboratory accessibility.
908 Devices (Nasdaq: MASS) reported Q2 2021 revenue of $8.3 million, marking a 49% increase from Q1 2021 but a 26% decline year-over-year due to a one-time shipment in Q2 2020. Desktop sales surged 70% compared to last year, contributing a third of total revenue. The company anticipates full-year revenue growth of 49% to 60%, adjusting guidance upward to $40-$43 million. Gross profit decreased to $4.4 million with a margin of 53%. Operating expenses rose to $11.8 million, resulting in a net loss of $7.4 million, or $0.27 per share. Cash reserves stand at $141 million.
908 Devices (NASDAQ: MASS) has announced the appointment of six new members to its Scientific Advisory Board (SAB), enhancing its expertise in proteomics. The new members, including renowned scientists like Prof. Ileana Cristea and Prof. John Yates, bring extensive knowledge in areas such as viral infection and mass spectrometry. Company leaders expect these additions will strengthen the development of their mass spectrometry and microfluidic technologies. This expansion follows the recent advancements in their platform capabilities for analyzing complex biological samples.
908 Devices (NASDAQ:MASS) has announced the expansion of its global channel distribution network, now spanning over 40 countries across six continents. CEO Kevin J. Knopp emphasized the company's commitment to supporting sales and customer demands as part of their 2021 growth strategy. Recent partnerships include Sartorius Korea Biotech, Rhenium Ltd. in Israel, and others across South America and Europe. To bolster this initiative, additional sales and support staff have been hired in key regions. This strategic growth aims to enhance the company's presence in critical markets for its handheld and desktop mass spectrometry devices.
908 Devices (NASDAQ:MASS) announced a successful collaboration with Transcenta, enhancing biopharmaceutical workflows in Hangzhou, China. Their ZipChip® device accelerated the measurement of monoclonal antibodies (mAbs), achieving results in under 10 minutes—100 times faster than traditional methods. Transcenta also adopted the REBEL® device for near real-time amino acid analysis, supporting continuous cell culture. This partnership highlights the efficacy of 908 Devices' tools in bioprocess improvements and emphasizes their growing presence in the Asia Pacific region.
908 Devices Inc. (Nasdaq: MASS) announced it will release its financial results for Q2 2021 on August 4, 2021, before market open. A conference call will follow at 5:30 a.m. PT / 8:30 a.m. ET, available via live webcast on the company’s website. The session will be archived for replay within 24 hours. 908 Devices specializes in mass spectrometry devices that serve critical applications in life sciences and forensics, showcasing its commitment to making laboratory tools more accessible.
908 Devices (NASDAQ:MASS) has announced partnerships with Sartorius and Securecell to enhance its REBEL™ platform for bioprocess labs. These integrations allow users to harness advanced data analytics and improve operational excellence in process development. Key features include seamless data flow from REBEL into Sartorius’ SIMCA for better data visualization and trend analysis, as well as enhanced monitoring capabilities with Securecell’s Lucullus for Critical Process Parameters. This collaboration aims to empower customers with actionable bioanalytics information and drive high yields in bioprocessing.